[go: up one dir, main page]

IN2014DN10084A - - Google Patents

Info

Publication number
IN2014DN10084A
IN2014DN10084A IN10084DEN2014A IN2014DN10084A IN 2014DN10084 A IN2014DN10084 A IN 2014DN10084A IN 10084DEN2014 A IN10084DEN2014 A IN 10084DEN2014A IN 2014DN10084 A IN2014DN10084 A IN 2014DN10084A
Authority
IN
India
Prior art keywords
androgen receptor
receptor modulator
trifluoromethylpyridin
diazaspiro
methylbenzamide
Prior art date
Application number
Other languages
English (en)
Inventor
Nicholas D Smith
Mark R Herbert
Ouathek Ouerfelli
Anna Dilhas
Original Assignee
Aragon Pharmaceuticals Inc
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10084(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer filed Critical Aragon Pharmaceuticals Inc
Publication of IN2014DN10084A publication Critical patent/IN2014DN10084A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IN10084DEN2014 2012-06-07 2013-06-04 IN2014DN10084A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
IN2014DN10084A true IN2014DN10084A (sl) 2015-08-21

Family

ID=49712550

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10084DEN2014 IN2014DN10084A (sl) 2012-06-07 2013-06-04

Country Status (45)

Country Link
US (9) US9481663B2 (sl)
EP (4) EP3533792B1 (sl)
JP (3) JP6182209B2 (sl)
KR (2) KR102062024B1 (sl)
CN (3) CN105693692A (sl)
AU (3) AU2013271751B2 (sl)
BR (1) BR112014030678A2 (sl)
CA (4) CA3008345C (sl)
CL (1) CL2014003331A1 (sl)
CO (1) CO7240407A2 (sl)
CR (2) CR20190331A (sl)
CY (4) CY1120393T1 (sl)
DK (3) DK2858985T3 (sl)
EA (3) EA028791B1 (sl)
EC (1) ECSP14030098A (sl)
ES (3) ES2875932T3 (sl)
FR (1) FR21C1050I2 (sl)
GT (1) GT201400283A (sl)
HK (2) HK1210175A1 (sl)
HR (3) HRP20180902T1 (sl)
HU (4) HUE050357T2 (sl)
IL (5) IL320522A (sl)
IN (1) IN2014DN10084A (sl)
LT (4) LT2858985T (sl)
LU (1) LUC00236I2 (sl)
ME (2) ME03815B (sl)
MX (1) MX356754B (sl)
MY (1) MY187500A (sl)
NI (1) NI201400142A (sl)
NL (1) NL301144I2 (sl)
NO (1) NO2021046I1 (sl)
NZ (2) NZ717683A (sl)
PE (3) PE20150631A1 (sl)
PH (2) PH12014502714A1 (sl)
PL (3) PL3533792T3 (sl)
PT (3) PT2858985T (sl)
RS (3) RS57370B1 (sl)
SG (3) SG11201408140QA (sl)
SI (3) SI3533792T1 (sl)
SM (3) SMT202100355T1 (sl)
TR (1) TR201808939T4 (sl)
TW (1) TWI532732B (sl)
UA (2) UA123142C2 (sl)
WO (1) WO2013184681A1 (sl)
ZA (1) ZA201500076B (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
RS57370B1 (sr) 2012-06-07 2018-08-31 Aragon Pharmaceuticals Inc Kristalni oblici modulatora receptora androgena
CN105358535B (zh) 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
SG10201902568YA (en) 2012-09-26 2019-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP2017525727A (ja) * 2014-08-26 2017-09-07 アスター バイオテック リミテッド ライアビリティ カンパニー プロテインキナーゼ阻害剤
MD3226841T2 (ro) 2014-12-05 2025-06-30 Aragon Pharmaceuticals Inc Compoziții anticancerigene
WO2016090105A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions
PL3226842T3 (pl) 2014-12-05 2021-07-12 Aragon Pharmaceuticals, Inc. Kompozycje przeciwnowotworowe
US9888543B2 (en) 2014-12-19 2018-02-06 Lutron Electronics Co, Inc. Multi-channel lighting fixture having multiple light-emitting diode drivers
WO2017209939A1 (en) 2016-06-03 2017-12-07 Aragon Pharmaceuticals, Inc. Anticancer compositions
WO2018112001A1 (en) 2016-12-13 2018-06-21 Watson Laboratories Inc. Solid state forms of apalutamide
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
US20200270226A1 (en) * 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
WO2021033098A1 (en) * 2019-08-22 2021-02-25 Dr. Reddy’S Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
ES2588606T3 (es) 2006-03-27 2016-11-03 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
SG10201408699TA (en) * 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CN102884057B (zh) * 2010-02-16 2016-09-14 亚拉冈制药公司 雄激素受体调节剂及其用途
RS57370B1 (sr) 2012-06-07 2018-08-31 Aragon Pharmaceuticals Inc Kristalni oblici modulatora receptora androgena
US20200270226A1 (en) 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof

Also Published As

Publication number Publication date
JP6182209B2 (ja) 2017-08-16
RS57370B1 (sr) 2018-08-31
SI2858985T1 (sl) 2018-12-31
PH12016501470B1 (en) 2021-12-10
LTPA2021525I1 (sl) 2021-11-25
EP3533792B1 (en) 2021-05-05
CN104619692A (zh) 2015-05-13
IL236055A0 (en) 2015-02-01
PL3533792T3 (pl) 2021-11-29
JP2018141009A (ja) 2018-09-13
CR20190331A (es) 2019-11-12
CA2875767C (en) 2018-08-14
CY1120393T1 (el) 2019-07-10
TW201402561A (zh) 2014-01-16
CR20140549A (es) 2015-04-06
CY2021032I1 (sl) 2022-03-24
CN113135892A (zh) 2021-07-20
CL2014003331A1 (es) 2016-03-04
NZ702203A (en) 2016-09-30
EA201992010A1 (ru) 2020-01-24
MX2014015005A (es) 2015-09-04
FR21C1050I1 (fr) 2021-12-10
UA115665C2 (uk) 2017-12-11
ES2809738T3 (es) 2021-03-05
KR20150021993A (ko) 2015-03-03
SMT202000496T1 (it) 2020-11-10
CN105693692A (zh) 2016-06-22
PE20200795A1 (es) 2020-08-10
AU2017279807B2 (en) 2018-11-08
HRP20201387T1 (hr) 2020-11-27
EA033956B1 (ru) 2019-12-13
SMT202100355T1 (it) 2021-07-12
EP2858985B1 (en) 2018-04-18
AU2017279807A1 (en) 2018-01-25
JP2015518890A (ja) 2015-07-06
RS60617B1 (sr) 2020-09-30
PT3348553T (pt) 2020-09-28
IL259738A (en) 2018-07-31
IL267608B1 (en) 2025-06-01
SMT201800311T1 (it) 2018-07-17
US20210163441A1 (en) 2021-06-03
ES2875932T3 (es) 2021-11-11
LUC00236I2 (sl) 2025-02-03
NZ717683A (en) 2018-04-27
US20250092011A1 (en) 2025-03-20
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
HK1210175A1 (en) 2016-04-15
UA123142C2 (uk) 2021-02-24
HUE038082T2 (hu) 2018-09-28
NO2021046I1 (no) 2021-11-02
CY1124831T1 (el) 2022-03-24
EP3533792A1 (en) 2019-09-04
ME03815B (me) 2021-04-20
EP2858985A1 (en) 2015-04-15
EA201791592A1 (ru) 2018-01-31
DK3348553T3 (da) 2020-07-27
US10308630B2 (en) 2019-06-04
CA3055660A1 (en) 2013-12-12
HRP20210909T1 (hr) 2021-09-03
TWI532732B (zh) 2016-05-11
PH12014502714B1 (en) 2015-02-02
KR20190132543A (ko) 2019-11-27
CA3008345A1 (en) 2013-12-12
GT201400283A (es) 2017-07-03
TR201808939T4 (tr) 2018-07-23
US12018008B2 (en) 2024-06-25
SG11201408140QA (en) 2015-01-29
HK1226066A1 (zh) 2017-09-22
CO7240407A2 (es) 2015-04-17
US20190330182A1 (en) 2019-10-31
PT3533792T (pt) 2021-06-07
PE20150631A1 (es) 2015-05-11
CA3114726A1 (en) 2013-12-12
AU2017200298B2 (en) 2017-09-28
US20200115361A1 (en) 2020-04-16
MY187500A (en) 2021-09-24
LT2858985T (lt) 2018-09-25
EP3348553B1 (en) 2020-07-08
AU2013271751B2 (en) 2017-02-23
US20180258067A1 (en) 2018-09-13
AU2017200298A1 (en) 2017-02-02
US10526310B2 (en) 2020-01-07
PE20200725A1 (es) 2020-07-21
KR102062024B1 (ko) 2020-01-03
DK2858985T3 (en) 2018-05-28
IL267608A (en) 2019-08-29
HUS2100047I1 (hu) 2021-11-29
US10556882B2 (en) 2020-02-11
NL301144I2 (nl) 2025-03-20
RS61988B1 (sr) 2021-07-30
PT2858985T (pt) 2018-07-10
SG10201610248SA (en) 2017-02-27
EP2858985A4 (en) 2016-05-25
US20150133481A1 (en) 2015-05-14
JP6345821B2 (ja) 2018-06-20
PH12014502714A1 (en) 2015-02-02
JP2017178923A (ja) 2017-10-05
ME03081B (me) 2019-01-20
WO2013184681A1 (en) 2013-12-12
US10766875B2 (en) 2020-09-08
SI3348553T1 (sl) 2020-11-30
US9994545B2 (en) 2018-06-12
IL320522A (en) 2025-06-01
US20170001977A1 (en) 2017-01-05
LT3348553T (lt) 2020-09-25
DK3533792T3 (da) 2021-06-28
IL259738B (en) 2021-06-30
PL2858985T3 (pl) 2018-09-28
PH12016501470A1 (en) 2017-07-10
EP3348553A1 (en) 2018-07-18
SG10201610249TA (en) 2017-02-27
FR21C1050I2 (fr) 2024-05-24
US20200354335A1 (en) 2020-11-12
SI3533792T1 (sl) 2021-11-30
US20190241539A1 (en) 2019-08-08
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
HRP20180902T1 (hr) 2018-08-24
IL275413A (en) 2020-07-30
MX356754B (es) 2018-06-11
EA201492272A1 (ru) 2015-05-29
BR112014030678A2 (pt) 2017-06-27
LT3533792T (lt) 2021-07-26
EA028791B1 (ru) 2017-12-29
ZA201500076B (en) 2016-10-26
EP3922629A1 (en) 2021-12-15
HUE054595T2 (hu) 2021-09-28
ECSP14030098A (es) 2016-01-29
CA2875767A1 (en) 2013-12-12
KR102195916B1 (ko) 2020-12-30
PL3348553T3 (pl) 2021-02-08
CY2021032I2 (el) 2022-03-24
CA3008345C (en) 2019-10-22
CY1123427T1 (el) 2021-12-31
AU2013271751A1 (en) 2014-12-18
US9481663B2 (en) 2016-11-01

Similar Documents

Publication Publication Date Title
IN2014DN10084A (sl)
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
NZ702663A (en) Nuclear transport modulators and uses thereof
IN2012DN02735A (sl)
IN2012DN00754A (sl)
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
MX2015007051A (es) Diazol lactamas.
MX353331B (es) Formas solidas de clorhidrato de (1r,4r)-6´-fluoro-n,n-dimetil-4-f enil-4´,9´-dihidro-3´h-espiro-[ciclohexano-1,1´-pirano[3,4,b]indo l]-4-amina.
MX2015012043A (es) Agonistas muscarinicos.
WO2015079415A9 (en) Amorphous cobicistat solid dispersion
UA115310C2 (uk) СПІРОЦИКЛІЧНІ СПОЛУКИ НА ОСНОВІ ПОХІДНИХ 2-ОКСІНДОЛУ, ЯКІ МІСТЯТЬ ЯДРО СПІРО[ІНДОЛО-3,1'-ПІРОЛО[3,4-c]ПІРОЛУ] ТА ЗАЛИШКИ БІОГЕННИХ СІРКОВМІСНИХ АМІНОКИСЛОТ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ НА ЇХ ОСНОВІ
TN2011000063A1 (en) Quinuclidine carbonate derivatives and medicinal composition thereof